Given a context passage, generate a question from the passage such that its answer is shortest continous span from the passage.

[EX Q]: It was a comfortable sunny Sunday. I was going to meet an old university friend I hadn't seen for years, and was really excited to hear all his news. My train was running a little late, but that was no big problem - I could text him to say I would be delayed. He would understand. But... where was my mobile phone? I had that familiar sinking feeling. Yes, I'd forgotten it at home. No mobile phone. I'm sure I'm not alone in feeling anxious, _ and worried when I don't have my phone with me. In fact, I know I'm not alone: two-thirds of us experience 'nomophobia', the fear of being out of mobile phone contact. That's according to a study from 2012 which surveyed 1,000 people in the UK about their relationship with mobile phones. It says we check our mobile phones 34 times a day, that women are more 'nomophobic'than men, and that 18-24 year-olds are the most likely to suffer fear of being without their mobiles: 77% of them say they are unable to be apart from their phones for more than a few minutes. Do you have nomophobia ? * You never turn your phone off * You obsessively check for texts, missed calls and emails* You always take your phone to the bathroom with you* You never let the battery run out It's funny to think that around 20 years ago the only people with mobile phones would be businessperson carrying their large, plastic 'bricks'. Of course, these days, mobile phones are everywhere. A UN study from this year said mobile phone subscriptions would outnumber people across the world by the end of 2014. And when there are more phones than people in the world, maybe it's time to ask who really is in charge? Are you in control of your phone, or does your phone control you? So, what happened with my university friend? When I arrived a few minutes late he just laughed and said: "You haven't changed at all - still always late!" And we had a great afternoon catching up, full of jokes and stories, with no interruptions and no nagging desire to check my phone. Not having it with me felt strangely liberating. Maybe I'll leave it at home on purpose next time.
[EX A]: Which word is used to describe old mobile phones according to the passage?

[EX Q]: A Vampyre Story is a 2008 point-and-click adventure game developed by Autumn Moon Entertainment for Windows, published by Crimson Cow.
[EX A]: Which company developed the videogame A Vampyre Story?

[EX Q]: Our objective was to evaluate the efficacy of influenza and meningococcal vaccinations in healthy subjects exposed to the anti-interleukin-17A (IL-17A) monoclonal antibody (MAb) secukinumab. We used an open-label, parallel-group, randomized single-center study of 50 healthy subjects. Subjects received a single 150-mg dose of secukinumab or no treatment, followed by vaccination with inactivated trivalent subunit influenza virus and conjugate group C meningococcal vaccine (Agrippal and Menjugate, respectively) 2 weeks later. Primary efficacy variables were responses of 4-fold increases in antibody titer (hemagglutination inhibition [HI; for influenza virus] and serum bactericidal assay [SBA; for Neisseria meningitides]) for meningococcus and influenza (at least two out of three serotypes), both at 4 weeks postvaccination. All subjects randomized to secukinumab (n = 25) or the control (n = 25) completed the study. Antibody responses to vaccinations measured at 4 weeks were comparable in both groups, with 4-fold increased responses following influenza virus vaccination of 20/25 (80%) for both groups and following meningococcal vaccination of 19/25 (76%) for the secukinumab group and 18/25 (72%) for the control group. Differences between groups were 0% (90% confidence intervals [CI], 19 and 19%) and 4% (90% CI, 16 and 24%) for influenza virus and meningococcal vaccines, respectively. Antibody responses were comparable between the 2 groups at different time points. Headache was the most frequently reported adverse effect. No deaths or serious adverse events were reported. Blockade of IL-17A by secukinumab does not appear to interfere with efficacy of influenza and meningococcal vaccinations, as assessed by the achievement of protective antibody levels. A protective (4-fold) immune response to both vaccinations at 4 weeks was achieved in 80 and 76% of subjects exposed to secukinumab and the control, respectively.
[EX A]:
Which molecule is targeted by a monoclonal antibody Secukinumab?